Skip to content

Regencell Bioscience

US · RGC #2393 by market cap Listed 2021
4.18 -0.18 -4.13%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:34

Price chart

Pre-market 4.48 +2.75%
After-hours 4.18 0.00%
Overnight 4.49 +2.98%
24.314.184.182026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on RGC?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -45.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days E → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 08:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall D

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth C-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) 0.0% Better than 24%
Net income CAGR (3Y) 2.1% Better than 45%
Free cash flow CAGR (3Y) -6.0% Better than 32%
Profitability C

How much profit the business keeps from each dollar of sales and capital.

Gross margin 62.3% Better than 77%
Operating margin 8.6% Better than 47%
Net margin 3.6% Better than 38%
Return on equity -128.5% Better than 4%
Return on invested capital -122.9% Better than 1%
Momentum D-

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -21.1% Better than 29%
6-month return -83.8% Better than 1%
12-month return (ex latest month) -38.5% Better than 6%
Distance below 52-week high 93.9% Better than 0%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 10.8x Better than 94%
Debt to assets 2.0% Better than 88%
Interest coverage 2.0x Better than 37%
Free cash flow / net income 142.0% Better than 62%
Analyst View N/A

What the Street thinks: share of Buy ratings and upside to the average target.

Not enough data to grade this factor.

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -15.38%
1M -60.00%
3M -23.16%
6M -84.74%
YTD -80.10%
1Y -66.88%
3Y +1,223.62%
5Y +483.15%

Key statistics

Price & volume

Prev close
4.36
Open
4.43
Day range
4.12 - 4.43
Avg price
4.25
Volume
111.05K
Turnover
471.88K
Amplitude
7.11%
52-week range
4.12 - 69.00

Valuation

P/E
-174.17
P/E (TTM)
-174.17
P/B
154.81
EPS
-0.02
Net profit
-11.90M
Net assets
13.39M

Share structure

Market cap
2.07B
Float cap
235.72M
Shares out
495.88M
Float shares
56.39M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2021-07-16
52-week range 0% of range
4.12 69.00

93.9% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+346.86K net over the window

Short interest

Shares short
349.51K
As of
2026-10-30

Frequently asked questions

What is the current stock price of Regencell Bioscience (RGC)?

Regencell Bioscience last traded at 4.18. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Regencell Bioscience's market cap?

About 2.07B.

What is the P/E ratio of Regencell Bioscience?

The trailing twelve-month P/E is -174.17. The Valuation tab shows it against the stock's own five-year range.

Does Regencell Bioscience pay a dividend?

Regencell Bioscience does not currently pay a regular dividend.

What is Regencell Bioscience's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Regencell Bioscience a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 19:34:41 · For reference only, not investment advice and not tailored to your situation.

Regencell Bioscience discussion 0 comments

Add a comment